Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2011

View Archived Issues

Sirukumab is safe in patients with rheumatoid arthritis, cutaneous and systemic lupus erythematosus

Galapagos discloses first-in-human data on GLPG-0634

OSI claims new inhibitors of insulin-like growth factor 1 receptor and/or insulin receptor

Eli Lilly describes new opioid NOP receptor antagonists

New lysophospholipid S1P1 receptor agonists presented by Receptos

Orchid Chemicals & Pharmaceuticals synthesizes new histone deacetylase inhibitors

Novel arylpiperazine-containing purine derivatives patented by Green Cross for depression

Merck & Co. changes prescribing information for simvastatin following FDA review of myopathy risk

Pharmasset expands treatment cohorts in trial of PSI-7977 in chronic hepatitis C

Anavex Life Sciences initiates scale-up manufacturing of lead compound ANAVEX 1-41

Seattle Genetics exercises option to codevelop second antibody-drug conjugate with Agensys

MK-2048 is a candidate therapy for adult T-cell leukemia / News in Context

Phase I trial assesses safety and tolerability of KW-2450 in pretreated advanced solid tumors

Intercell and Merck & Co. provide product updates

GQ-16 may provide safe PPAR-gamma activation for diabetes treatment

Merck Serono and Affectis sign agreement to develop oral P2X7 receptor antagonists

Galapagos' GLPG-0634 enters phase II trial in rheumatoid arthritis

Avila Therapeutics and NIAID enter agreement for preclinical evaluation of AVL-192

AVI BioPharma to revise protocol of phase II eteplirsen trial in Duchenne's muscular dystrophy

Telik initiates phase II trial of Telintra in lenalidomide-refractory or -resistant del 5q MDS

Marina Biotech completes dosing of first cohort in phase Ib/IIa CEQ-508 trial in FAP

Enrollment complete in pivotal phase III CENTRIC trial

Drug safety monitoring board recommends advancing DIGNITY to phase II

Benefits sustained at 18 months in APOLLO trial of cardiac cell therapy after heart attack

Xgeva approved in Canada to reduce risk of skeletal-related events due to certain bone metastases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...